{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,4,25]],"date-time":"2025-04-25T04:09:36Z","timestamp":1745554176609,"version":"3.40.4"},"reference-count":4,"publisher":"S. Karger AG","issue":"3","license":[{"start":{"date-parts":[[2002,1,1]],"date-time":"2002-01-01T00:00:00Z","timestamp":1009843200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.karger.com\/Services\/SiteLicenses"},{"start":{"date-parts":[[2002,1,1]],"date-time":"2002-01-01T00:00:00Z","timestamp":1009843200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.karger.com\/Services\/SiteLicenses"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Digestion"],"published-print":{"date-parts":[[2002]]},"abstract":"<jats:p>&lt;i&gt;Background:&lt;\/i&gt; Rabeprazole has been demonstrated to be a potent antisecretory agent and has been shown to be clinically effective in the treatment of acid-related diseases. &lt;i&gt;Aims:&lt;\/i&gt; It was to determine the efficacy of rabeprazole at 20 and 40 mg in addition to amoxicillin and clarithromycin in the treatment of active &lt;i&gt;Helicobacter pylori&lt;\/i&gt;-positive duodenal ulcers compared with omeprazole 40\u00a0mg. &lt;i&gt;Patients and Methods:&lt;\/i&gt; One hundred and twenty-seven patients were randomised into three treatment groups: 40 patients were treated with rabeprazole 40 mg daily, 42 patients with rabeprazole 20 mg daily and 45 patients with omeprazole 40 mg daily for 10 days. All patients received amoxicillin 1 g twice a day and clarithromycin 500 mg twice a day for 5 days. All patients were re-assessed at least 4 weeks after the end of the treatment. &lt;i&gt;Results:&lt;\/i&gt; According to the intention-to-treat (ITT) protocol, ulcer healing was observed in 90% of patients in the rabeprazole 40 group, in 85.7% in the rabeprazole 20 group and in 93.3% in the omeprazole 40 group. We observed &lt;i&gt;H. pylori&lt;\/i&gt; eradication in 90% ITT in the rabeprazole 40 group, in 80.9% ITT in the rabeprazole 20 group and in 88.8% ITT in the omeprazole 40 group. Statistical analysis did not show significant differences among the three groups. &lt;i&gt;Conclusions:&lt;\/i&gt; A 10-day rabeprazole 20 mg regimen represents an efficacious and safe regimen for &lt;i&gt;H. pylori&lt;\/i&gt; eradication and ulcer healing.<\/jats:p>","DOI":"10.1159\/000066756","type":"journal-article","created":{"date-parts":[[2003,4,15]],"date-time":"2003-04-15T21:05:40Z","timestamp":1050440740000},"page":"154-159","source":"Crossref","is-referenced-by-count":8,"title":["Eradication Therapy with Rabeprazole versus Omeprazole in the Treatment of Active Duodenal Ulcer"],"prefix":"10.1159","volume":"66","author":[{"given":"F.","family":"Catalano","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"C.","family":"Terminella","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"G.","family":"Branciforte","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"C.","family":"Bentivegna","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A.","family":"Brogna","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A.","family":"Scalia","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"127","published-online":{"date-parts":[[2002,12,19]]},"reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1046\/j.1523-5378.1998.08029.x"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1097\/00004836-200009000-00008"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2036.1998.00382.x"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2036.2001.01118.x"}],"container-title":["Digestion"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.karger.com\/Article\/Pdf\/66756","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.karger.com\/Article\/Pdf\/66756","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,24]],"date-time":"2025-04-24T03:19:50Z","timestamp":1745464790000},"score":1,"resource":{"primary":{"URL":"https:\/\/karger.com\/article\/doi\/10.1159\/000066756"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2002]]},"references-count":4,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2002,7,1]]}},"URL":"https:\/\/doi.org\/10.1159\/000066756","archive":["Portico"],"relation":{},"ISSN":["0012-2823","1421-9867"],"issn-type":[{"type":"print","value":"0012-2823"},{"type":"electronic","value":"1421-9867"}],"subject":[],"published":{"date-parts":[[2002]]}}}